Imbalance between CaM kinase II and calcineurin activities impairs caffeine-induced calcium release in hypertrophic cardiomyocytes

Biochemical Pharmacology

Volumn 74, Issue 12, 2007, Pages 1727-1737

  Lu, Ying Mei ^a   Shioda, Norifumi ^a   Han, Feng ^a   Moriguchi, Shigeki ^a   Kasahara, Jiro ^a   Shirasaki, Yasufumi ^b   Qin, Zheng Hong ^c   Fukunaga, Kohji ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b DAIICHI SANKYO CO   (Japan)

^c MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

Calcineurin; CaMKII; Cardiomyocyte; DY 9760e; Hypertrophy; Phospholamban

Indexed keywords

ANGIOTENSIN II; CAFFEINE; CALCINEURIN; DY 9760E; DY 9836; DYSTROPHIN; ENDOTHELIN; PHENYLEPHRINE; PHOSPHOLAMBAN; PROTEIN KINASE (CALCIUM,CALMODULIN) II; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; CALCIUM MOBILIZATION; CALCIUM SIGNALING; CALCIUM TRANSPORT; CONTROLLED STUDY; ENZYME ACTIVITY; HEART MUSCLE CELL; HEART MUSCLE RELAXATION; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SARCOPLASMIC RETICULUM;

ANGIOTENSIN II; ANIMALS; CALCINEURIN; CALCIUM; CALCIUM-BINDING PROTEINS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CARDIOMEGALY; CELLS, CULTURED; ENDOTHELIN-1; IMMUNOHISTOCHEMISTRY; INDAZOLES; PHENYLEPHRINE; PHOSPHORYLATION; RATS; RATS, WISTAR;

EID: 36049031562     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.08.022     Document Type: Article

References (65)

1. Packer M., O'Connor C.M., Ghali J.K., Pressler M.L., Carson P.E., Belkin R.N., et al. Effect of amlodipine on morgidity and mortality in severe chronic heart failure. N Engl J Med 335 (1996) 1107-1114
2. Cohn J.N., and Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
3. Carafoli E., Santella L., Branca D., and Brini M. Generation, control and processing of cellular calcium singnals. Crit Rev Biochem Mol Biol 36 (2001) 107-260
4. Muth J.N., Varadi G., and Schwartz A. Use of transgenic mice to study voltage-dependent Ca channels. Trends Pharmacol Sci 22 (2001) 526-532
5. Fabiato A. Time and calcium dependence of activation and inactivation of calcium-induced release of calcium from the sarcoplasmic reticulum of a skinned canine cardiac Purkinje cell. J Gen Physiol 85 (1985) 247-289
6. Hasenfuss G., Meyer M., Schillinger W., Preuss M., Pieske B., and Just H. Calcium handling proteins in the failing human heart. Basic Res Cardiol 92 (1997) 87-93
7. Houser S.R., Piacentino III V., and Weisser J. Anormalities of calcium cycling in the hypertrophied and failing heart. J Mol Cell Cardiol 32 (2000) 1595-1607
8. Gruver C.L., DeMayo F., Goldstein M.A., and Means A.R. Targeted developmental overexpression of calmodulin induced proliferative and hypertrophic growth of cardiomyocytes in transgenic mice. Endocrinology 133 (1993) 376-388
9. Hardingham G.E., Chawla S., Johnson C.M., and Bading H. Distinct functions of nuclear and cytoplasmic calcium in the control of gene expression. Nature 385 (1997) 260-265
10. Molkentin J.D., Lu J.R., Antos C.L., Markham B., Richardson J., Robbins J., et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93 (1998) 215-228
11. Molkentin J.D., and Dorn II G.W. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 63 (2001) 391-426
12. 2+/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity. J Biol Chem 277 (2002) 1261-1267
13. 2+ release. Circ Res 92 (2003) 904-911
14. Sei C.A., Irons C.E., Sprenkle A.B., McDonough P.M., Brown J.H., and Glembotski C.C. The alpha-adrenergic stimulation of atrial natriuretic factor expression in cardiac myocytes requires calcium influx, protein kinase C, and calmodulin-regulated pathways. J Biol Chem 266 (1991) 15910-15916
15. 2+/calmodulin-dependent protein kinase II regulates atrial natriuretic factor gene expression in ventricular myocytes. J Biol Chem 272 (1997) 31203-31208
16. 2+/calmodulin-dependent kinase II and calcineurin play critical roles in endothelin-1-induced cardiomyocyte hypertrophy. J Biol Chem 275 (2000) 15239-15245
17. 2+/calmodulin-dependent protein kinase II delta-subunit isoforms in rats with hypertensive cardiac hypertrophy. Mol Cell Biochem 220 (2001) 69-76
18. Hempel P., Hoch B., Bartel S., and Karczewski P. Hypertrophic phenotype of cardiac calcium/calmodulin-dependent protein kinase II is reversed by angiotensin converting enzyme inhibition. Basic Res Cardiol 97 (2002) I96-I101
19. Oka T., Dai Y.S., and Molkentin J.D. Regulation of calcineurin through transcriptional induction of the calcineurin A beta promoter in vitro and in vivo. Mol Cell Biol 25 (2005) 6649-6659
20. Goldspink P.H., McKinney R.D., Kimball V.A., Geenen D.L., and Buttrick P.M. Angiotensin II induced cardiac hypertrophy in vivo is inhibited by cyclosporin A in adult rats. Mol Cell Biochem 226 (2001) 83-88
21. Murat A., Pellieux C., Brunner H.R., and Pedrazzini T. Calcineurin blockade prevents cardiac mitogen-activated protein kinase activation and hypertrophy in renovascular hypertension. J Biol Chem 275 (2000) 40867-40873
22. Lai M.M., Burnett P.E., Wolosker H., Blackshaw S., and Snyder S.H. Cain, a novel physiologic protein inhibitor of calcineurin. J Biol Chem 273 (1998) 18325-18331
23. Wilkins B.J., De Windt L.J., Bueno O.F., Braz J.C., Glascock B.J., Kimball T.F., et al. Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth. Mol Cell Biol 22 (2002) 7603-7613
24. Bers D.M., and Guo T. Calcium signaling in cardiac ventricular myocytes. Ann NY Acad Sci 1047 (2005) 86-98
25. Simmerman H.K., Collins J.H., Theibert J.L., Wegener A.D., and Jones L.R. Sequence analysis of PLB: identification of phosphorylation sites and two major structural domains. J Biol Chem 261 (1986) 13333-13341
26. Brittsan A.G., and Kranias E.G. Phospholamban and cardiac contractile function. J Mol Cell Cardiol 32 (2000) 2131-2139
27. Sulakhe P.V., Vo X.T., Morris T.E., Pato M.D., and Khandelwal Rl. Protein phosphorylation in rat cardiac microsomes: effects if inhibitors of protein kinase A and of phosphatases. Mol Cell Biochem 175 (1997) 109-115
28. Mulkey R.M., Endi S., and Malenka R.C. Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal longterm depression. Nature 369 (1994) 486-488
29. Arahata K., Ishiura S., Ishiguro T., and Tsukahara T. Immunostaining of skeletal and cardiac surface membrane with antibody against Duchenne muscular dystrophy peptide. Nature 333 (1988) 861-863
30. Maeda M., Biro S., Kamogawa Y., Hirakawa T., Setoguchi M., and Tei C. Dystrophin upregulation in pressure-overloaded cardiac hypertrophy in rats. Cell Motil Cytoskel 55 (2003) 26-35
31. Ortiz-Lopez R., Hua L., Su J., Goytia V., and Towbin J.A. Evidence for a dystrophin missense mutantion as a cause of X-linked dilated cardiomyopathy. Circulation 95 (1997) 2434-2440
32. Badorff C., Lee G.H., Lamphear B.L., Martone M.E., Campbell K.P., Rhoads R.E., et al. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 5 (1999) 320-326
33. Towbin J.A. The role of cytoskeletal proteins in cardiomyopathies. Curr Opin Cell Biol 10 (1998) 131-139
34. Towbin J.A., Bowles K.R., and Bowles N.E. Etiologies of cardiomyopathy and heart failure. Nat Med 5 (1999) 266-267
35. Toyo-Oka T., Kawada T., Nakata J., Xie H., Urabe M., Masui F., et al. Translocation and cleavage of myocardial dystrophin as a common pathway to advanced heart failure: a scheme for the progression of cardiac dysfunction. Proc Natl Acad Sci USA 101 (2004) 7381-7385
36. Kawada T., Masui F., Tezuka A., Ebisawa T., Kumagai H., Nakazawa M., et al. A novel scheme of dystrophin disruption for the progression of advanced heart failure. Biochim Biophys Acta 1751 (2005) 73-81
37. Madhavan R., Massom L.R., and Jarrett H.W. Calmodulin specifically binds three proteins of the dystrophin-glycoprotein complex. Biochem Biophys Res Commun 185 (1992) 753-759
38. 2+-calmodulin binds to the carboxyl-terminal domain of dystrophin. J Biol Chem 271 (1996) 6605-6610
39. Suzuki A., Yoshida M., Hayashi K., Mizuno Y., Hagiwara Y., and Ozawa E. Molecular organization at the glycoprotein-complex-binding site of dystrophin. Three dystrophin-associated proteins bind directly to the carboxy-terminal portion of dystrophin. Eur J Biochem 220 (1994) 283-292
40. Han F., Shirasaki Y., and Fukunaga K. 3-[2-[4-(3-Chloro-2-methylphenylmethyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydro-chloride 3.5 hydrate (DY-9760e) is neuroprotective in rat microsphere embolism: role of the cross-talk between calpain and caspase-3 through calpastatin. J Pharmacol Exp Ther 317 (2006) 529-536
41. Waspe L.E., Ordahl C.P., and Simpson P.C. The cardiac beta-myosin heavy chain isogene is induced selectively in alpha 1-adrenergic receptor-stimulated hypertrophy of cultured rat heart myocytes. J Clin Invest 85 (1990) 1206-1214
42. 2+]i during caffeine contractures in rabbit cardiac myocytes. J Physiol (Lond) 453 (1992) 591-608
43. Laemmli U.K. Cleavage of structure proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
44. 2+ and calmodulin-dependent protein kinase from rat brain. J Neurochem 39 (1982) 1607-1617
45. 2+/calmodulin-dependent protein kinase II-dependent long-term potentiation in the rat suprachiasmatic nucleus and its inhibition by melatonin. J Neurosci Res 70 (2002) 799-807
46. Fukunaga K., Muller D., Ohmitsu M., Bako E., DePaoli-Roach A.A., and Miyamaoto E. Decreased protein phosphatase 2A activity in hippocampal long-term potentiation. J Neurochem 74 (2000) 807-817
47. Zhang T., Maier L.S., Dalton N.D., Miyamoto S., Ross Jr. J., Bers D.M., et al. The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ Res 92 (2003) 912-919
48. Marks A.R. Calcium and the heart: a question of life and death. J Clin Invest 111 (2003) 597-600
49. Balke C.W., and Shorofsky S.R. Alterations in calcium handling in cardiac hypertrophy and heart failure. Cardiovasc Res 37 (1998) 290-299
50. Taigen T., De Windt L.J., Lim H.W., and Molkentin J.D. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci USA 97 (2000) 1196-1201
51. Maier L.S. CaMKII overexpression in hypertrophy and heart failure: cellular consequences for excitation-contraction coupling. Braz J Med Res 38 (2005) 1293-1302
52. 2+ handling in a calcinerin transgenic model of heart failure. Cardiovasc Res 54 (2002) 105-116
53. Kim S., and Iwao H. Molecular and cellular mechanisms if angiotensin II-mediated cardiovascular and renal diseases. Pharmacil Rev 52 (2000) 11-34
54. Dorn II G.W., and Brown J.H. Gq signaling in cardiac adaptation and maladaptation. Trends Cardiovasc Med 9 (1999) 26-34
55. Yamazaki T., Komuro I., Kudoh S., Zou Y., Shiojima I., Hiroi Y., et al. Endothlin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem 271 (1996) 3221-3228
56. Yang B., Ibraghimov-Beskrovnaya O., Moomaw C.R., Slaughter C.A., and Campbell K.P. Heterogeneity of the 59-kDa dystrophin-associated protein revealed by cDNA cloning and expression. J Biol Chem 269 (1994) 6040-6044
57. Bonet-Kerrache A., Fabbrizio E., and Mornet D. N-terminal domain of dystrophin. FEBS Lett 355 (1994) 49-53
58. Fabbrizio E., Bonet-Kerrache A., Limas F., Hugon G., and Mornet D. Dystrophin, the protein that promotes membrane resistance. Biochem Biophys Res Commun 213 (1995) 295-301
59. Takada Y., Hashimoto M., Kasahara J., Aihara K., and Fukunaga K. Cytoprotective effect of sodium orthovanadate on ischemia/reperfusion-induced injury in the rat heart involves Akt activation and inhibition of fodrin breakdown and apoptosis. J Pharmacol Exp Ther 311 (2004) 1249-1255
60. Hashimoto M., Takada Y., Takeuchi Y., Kasahara J., Hisa H., Shirasaki Y., et al. Cytoprotective effect of 3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate (DY-9760e) against ischemia/reperfusion-induced injury in rat heart involves inhibition of fodrin breakdown and protein tyrosine nitration. J Pharmacol Sci 98 (2005) 142-150
61. Hein S., Kostin S., Heling A., Maeno Y., and Schaper J. The role of the cytoskeleton in heart failure. Cardiovasc Res 45 (2000) 273-278
62. Ganote C.E., and Armstrong S.C. Dystrophin-associated protein complex and heart failure. Lancet 359 (2002) 905-906
63. Gwathmey J.K., Bentivegna L.A., Ransil B.J., Grossman W., and Morgan J.P. Relationship of abnormal intracellular calcium mobilisation to myocyte hypertrophy in human ventricular myocardium. Cardiovasc Res 27 (1993) 199-203
64. 2+/calmodulin-dependent protein kinase is altered in heart failure. Circ Res 86 (2000) 596-605
65. Hubbard M.J., and Klee C.B. Calmodulin binding by calcineurin. Ligand-induced renaturation of protein immobilized on nitrocellulose. J Biol Chem 262 (1987) 15062-15070